Haemophilus influenza type b resistant to both chloramphenicol and ampicillin in Britain
It is now standard practice to treat severe infections due to Haemophilus influenzae with either chloramphenicol alone or a combination of ampicillin and chloramphenicol. We describe a patient who twice became infected with a strain of H influenzae type b that was resistant to both ampicillin and chloramphenicol.
Case report A 9-year-old boy was diagnosed in 1979 as having dermatomyositis, which was treated with prednisolone with a satisfactory initial response. To reduce his dependency on steroids, salicylates, sodium etidronate, and penicillamine were introduced sequentially, starting in January 1981. In April a calcinotic lesion medial to the left knee became infected and discharged pus.
Routine swabs were taken and treatment started with flucloxacillin 50 mg/kg 24 hours and fusidic acid 20 mg/kg 24 Baseline observations of heart rate, blood pressure, and expiratory peak flow rate were recorded every 15 minutes for one hour and a blood sample taken.
Lignocaine injections were prepared from bottles of 1 % and 2 % plain lignocaine, free from preservative and vasoconstrictor. Dilutions of 1/10
(1 mg/ml), 1/100 (0-1 mg/ml), and 1/1000 (10 itg/ml) were made from 1 % lignocaine, labelled, and kept.
Chlorpheniramine 10 mg intramuscularly was given to the patient. Resuscitation agents were drawn up and placed by the patient's bed: adrenaline 1/1000 (1 ml for injection im), chlorpheniramine 10 mg (1 ml for injection iv), and hydrocortisone 100 mg (1 ml for injection iv).
CHALLENGE PROCEDURE
The patient was attended by a nurse throughout the test and the ward doctor was within one minute's call for 30 minutes.
Lignocaine injections were given as follows (intervals between doses were 60 minutes for immediate or 24 hours for late reactions): (a) intradermal injection of 0-02 ml at 1/1000 dilution; (b) subcutaneous injection of 0-05 ml at 1/100 dilution; (c) subcutaneous injection of 0-05 ml at 1/10 dilution; (d) subcutaneous injection of 0-05 ml undiluted 1 % lignocaine; (e) subcutaneous injection of 0-25 ml undiluted 2 % lignocaine; and (f) subcutaneous injection of 2-0 ml undiluted 2 % lignocaine. If no reaction occurred the patient was allowed home with an escort one hour after the last injection unless the history indicated that a reaction could occur after several hours.
Emergency procedures were adopted if any reaction other than a local weal or flare developed: all further doses of lignocaine were stopped, further blood samples taken, and the patient attended constantly.
Results-Three patients were atopic and three had immune-related disorders (fibrosing alveolitis, recurrent urticaria, asthma with nasal polyps, and aspirin intolerance). Two of the atopic patients had positive reactions to skin tests with lignocaine (weal >4 mm, flare >11 mm). No patient showed any detectable reaction to the direct challenge.
Comment
In each of our eight cases it would be safe for the patient to receive plain lignocaine for further dental or aural or nasopharyngeal treatment. They have all now received such treatment without adverse reactions. Our regimen did not exclude the possibility that other components of the original formulation of the local anaesthetic could have provoked the presenting reaction. Multidose phials of lignocaine may contain methylparaben preservatives as well as a vasoconstrictor. These are known immunogens which may elicit both immediate and delayed hypersensitivity.3 4The toxic effects of vasoconstrictors and of lignocaine itself5 are well known. Although these factors could have been ruled out in our patients, we had excluded hypersensitivity to lignocaine itself and therefore saw little justification for further investigation.
As far as the question of the test's safety is concerned, the starting dose was extremely low (0-2 pg); the presenting reactions had occurred with doses of 20-40 mg. This difference gives an adequate safety margin even if the patient is sensitised. Furthermore, our experience and published reports make us seriously doubt whether true anaphylaxis to lignocaine has ever been satisfactorily shown. Nevertheless, since this hypothesis can never be proved, every safety precaution must be taken during a direct challenge test with this drug. For practical purposes, the conclusion that our patients' presenting symptoms were not due to lignocaine hypersensitivity is adequate. As a precaution they have been advised not to receive any local anaesthetic preparation other than plain lignocaine, which is devoid of all preservatives and vasoconstrictors. We believe the benefits of the information gained from the direct challenge test far outweigh any potential risks.
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